Marinkovich Lab

Welcome to the Marinkovich Lab at Stanford School of Medicine!

U.S. Food and Drug Administration

FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

FDA approves Vyjuvek, a gene therapy for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in